Key Takeaways
- Sequential recovery, crop pain persists: Revenue rose 15% QoQ to ₹514 crores and EBITDA margin expanded 220 bps, but the crop protection business remains under severe pressure from Chinese oversupply and global destocking.
- Pharma margins have normalized: Pharma EBIT margin hit 15.9% in Q4 (full year 8.5%), driven by mix, stable raw material costs, and cost initiatives; management confirmed margins are now at a sustainable level.
- The growth CAPEX cycle is entering its payoff phase: The heavy lifting on animal health, the new Panoli multi-purpose facility, and other infrastructure is largely done; no major new CAPEX is planned, and the focus shifts to filling capacity over the next 2-3 years.
- Management set a bold top-line ambition: A 12-15% topline growth plan over 3-5 years, with a revenue target of ₹3,000 crores in 3-4 years and ₹6,000 crores before FY30, underpinned by pharma, animal health, and a crop recovery.
- What to watch next quarter: Whether the promised CDMO destocking normalization materializes by end-H1 FY25, any early signs of crop protection pricing recovery, and the pace of new enquiry conversion linked to the US BIOSECURE Act.
Crop Protection: The Overhang
- The core problem: Global crop protection is suffering a triple hit of inventory backlog at customers, massive Chinese overcapacity driving prices to rock bottom, and subdued end-market demand. All global innovator majors reported negative Q1 numbers.
- Pricing has found a floor, but recovery is distant: Management believes prices are not going down further and have hit rock bottom. Customers expect marginal improvement only once fresh orders start and inventory liquidates, a scenario roughly 6 to 9 months away.
- Recovery timeline is conservative and fluid: Management is guiding for improvement only toward the end of H2 FY25, and does not expect it before the middle of H2. The situation in China remains highly fluid, making any forecast uncertain.
- Volume drop compounds the price pain: Selling prices have fallen due to intense competition, and volumes have also declined significantly compared to last year, creating a double drag on the segment's revenue.
Sameer Hiremath: "I've spoken to each and every one of my customers in the world. I asked them this question. They said, 'Your guess is as good as mine.'"
Pharma: The Margin Recovery Story
- Margins have normalized: Pharma EBIT margin improved sharply to 15.9% in Q4, up from a full-year average of 8.5%. Management confirmed the improvement is sustainable, driven by a better product mix, stabilized raw material prices, and cost optimization under "Project Pinnacle."
- The growth algorithm is set: Management laid out a 12-15% topline growth plan over a 3-to-5-year horizon, built on volume growth in a focused set of APIs where Hikal aims to be the global cost leader.
- Regulatory barriers protect pharma from China: Unlike crop protection, pharma faces high barriers to entry from FDA and cGMP requirements. Management does not foresee the same level of Chinese overcapacity competition on the pharma side.
- Raw material costs are stable, for now: Pharma raw material prices have stabilized over the last two quarters, with visibility for stability over the next one quarter. No increases are currently anticipated.
- Seasonal caution on the margin run-rate: Q4 is always the strongest quarter; Q1 will see a 3-4 week annual plant shutdown that lowers utilization. Margins are sustainable, but quarterly revenue will reflect this seasonal pattern.
Manoj Mehrotra: "Definitely, 12-15% top line growth, that is our plan."
CDMO & New Growth Engines
- CDMO normalization is the nearest catalyst: Destocking has been a drag on the CDMO business, but management expects industry normalization toward the end of H1 FY25. Several custom audits are lined up for the rest of 2024, with operating leverage expected to improve profitability.
- The BIOSECURE Act opportunity is real but gradual: Initial signs are very promising, with an enhanced number of enquiries from US pharmaceutical companies. Management expects Hikal to benefit in the medium-to-long term as customers and regulators grow reluctant to rely on China.
- Molecule migration from China is underway: Enquiries about moving projects out of China are serious. Some NCE clinical-phase projects are already shifting, some have converted to R&D-stage projects, and more RFQs are coming in. The process is taking time but is happening.
- Animal health is the next leg of growth: The ₹140-145 crore multi-purpose plant at Panoli is commissioned, with 4 product validations completed and more underway. Validation takes 14-18 months before commercial supplies begin, so material revenue is expected in the next 2 years, with the business reaching critical size in 2-3 years.
- Food ingredients are commercial and ramping: Two products are in production with oriented customers in the US and Europe, expected to reach peak revenue by 2026.
- KSMs in the pipeline: Two KSMs are in Phase-III clinical trials with innovators, progressing well, and expected to reach full potential in 2026 or 2027.
Sameer Hiremath: "Customers and regulatory authorities on the pharma side are reluctant to go into China. And we're seeing in companies in India, like, Hikal will benefit from increased traction."
CAPEX, Capacity & Returns
- The heavy CAPEX cycle is behind us: No major new CAPEX is expected for the next year unless a big new contract or business requirement arises. Management is not averse to investing with a strong case, but the focus is now on filling recently built capacity.
- Growth CAPEX will start contributing from FY25: The major CAPEX of the last two years carries a gestation period of 2-3 years to ramp up volumes. Some impact will be visible this year, but the meaningful contribution begins next year and builds thereafter.
- Asset turns have declined structurally: Blended asset turns have come down from the 1.5-1.7x range on gross CAPEX to lower levels, driven by infrastructure upgradation and a more expensive CAPEX environment.
- Crop capacity is ready to deploy: Three capacities in crop protection can be deployed at short notice; management is winning contracts and expects to fill them very soon.
- Animal health CAPEX is complete: No additional CAPEX is planned for animal health currently; any future debottlenecking will be evaluated case-by-case, but the base investment is done.
Margins & Return Profile
- Q4 margin expansion was driven by operating leverage and cost control: EBITDA margin reached 18.4%, up 220 bps QoQ, on the back of lower raw material costs, improved operational efficiency, and a favorable product mix. Full-year EBITDA margin was 15%, up 230 bps YoY.
- The path back to 20%+ EBITDA margins: Management expects EBITDA margins to return to the plus-20% level in the next couple of years once all capacities start getting utilized and the growth CAPEX begins to pay off.
- ROCE recovery tied to utilization: ROCE is expected to move closer to the high teens in the next couple of years as full capacity comes on stream. The metric has been depressed by the recent CAPEX cycle and underutilization.
- Gross margin dynamics are favorable: Raw material prices came down faster than selling prices, and selling prices on the pharma side have stabilized. The company also improved operational efficiency and product mix, supporting gross margin expansion.
Sameer Hiremath: "Once this full capacity gets utilized and comes on stream in the next couple of years, we can see our ROCE will go up and closer to the high teens and margins will go, which is the most important metrics, our EBITDA margins will go in excess of 20%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CDMO destocking normalization | Industry normalization expected toward end of H1 | End of H1 FY25 |
| Crop protection recovery | Market trajectory to improve; conservative case is toward end of H2 | End of H2 FY25 |
| Crop protection pricing improvement | Customers expect marginal pricing improvement once inventory liquidates and fresh orders start | 6-9 months |
| Pharma topline growth | 12-15% topline growth plan | 3-5 year horizon |
| Revenue target | Achieve ₹3,000 crores revenue | 3-4 years |
| Revenue target | Achieve ₹6,000 crores revenue | Before FY30 |
| EBITDA margin | Return to 20%+ | Next couple of years |
| ROCE | Move closer to high teens | Next couple of years |
| Animal health commercial supplies | Validation takes 14-18 months; commercial quantities expected | Next 2 years |
| Animal health critical size | Business to reach critical size | Next 2-3 years |
| Food ingredients peak revenue | Two products reach peak revenue | 2026 |
| KSM Phase-III molecules | Reach full potential | 2026 or 2027 |
| All businesses return to pre-COVID levels | Growth and return to pre-COVID-type levels | Next 2-3 years |
| CDMO mix normalization | Return to ~50:50 CDMO:API mix once Phase-III molecules launch | At Phase-III launch |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹514 cr, +15% QoQ |
| EBITDA | ₹94 cr, +45% QoQ and +7% YoY |
| EBITDA margin | 18.4%, +220 bps QoQ |
| Pharma revenue | ₹338 cr, EBIT margin 15.9% |
| Pharma EBIT | ₹54 cr |
| Crop protection revenue | ₹177 cr, EBIT margin 7.7% |
| Crop protection EBIT | ₹14 cr |
| Full-year FY24 revenue | ₹1,785 cr |
| Full-year FY24 EBITDA | ₹267 cr, margin 15%, +230 bps YoY |
| Full-year FY24 Pharma revenue | ₹1,100 cr, EBIT margin 8.5% |
| Full-year FY24 Pharma EBIT | ₹93 cr |
| Full-year FY24 Crop revenue | ₹684 cr, EBIT margin ~11% |
| Full-year FY24 Crop EBIT | ₹74 cr |
| Total dividend FY24 | ₹1.2 per share, 60% of face value |
| CAPEX FY24 | ~₹230 cr, of which ~₹140-145 cr for animal health |
| CAPEX guidance FY25 | ₹100-120 cr, primarily debottleneck and infra |
| Pharma capacity utilization | ~80% |
| Crop protection capacity utilization | a little below 70% |
| Asset turns guidance | 1.1 to 1.3x on total CAPEX |
| Animal health revenue potential | ₹300-400 cr over next 4-5 years |
| CDMO repeat customer share | 85-90% |
| Generics repeat customer share | ~75% |
| Pharma Q4 FY24 sales growth | ~10% YoY (per an analyst's math) |
| Pharma Q4 FY24 profitability growth | ~50% YoY (per an analyst's math) |